These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36943661)

  • 1. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
    Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
    J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
    Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
    JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors.
    Lee A; Oley F; Lo M; Fong R; McGann M; Saunders I; Block S; Mahajan A; Pon TK
    Thromb Res; 2021 Dec; 208():148-155. PubMed ID: 34798446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of intracranial hemorrhage with direct oral anticoagulants vs low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Reed-Guy L; Desai AS; Phillips RE; Croteau D; Albright K; O'Neill M; Brem S; O'Rourke DM; Amankulor NM; Bagley SJ
    Neuro Oncol; 2022 Dec; 24(12):2172-2179. PubMed ID: 35551405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A; Williams H; Baer MR; Zimrin AB; Law JY
    Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism.
    Douros A; Filliter C; Azoulay L; Tagalakis V
    Thromb Res; 2021 Jun; 202():128-133. PubMed ID: 33836492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
    Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
    Shayeb AM; McManus HD; Urman D; Jani C; Zhang T; Dizman N; Meza L; Sivakumar A; Gan CL; Barata P; Bilen MA; Gao X; Heng D; Pal S; Narra R; Kilari D; Kaymakcalan MD; McGregor B; Choueiri TK; McKay RR
    Clin Genitourin Cancer; 2023 Feb; 21(1):55-62. PubMed ID: 36411184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.
    Carney BJ; Uhlmann EJ; Puligandla M; Mantia C; Weber GM; Neuberg DS; Zwicker JI
    J Thromb Haemost; 2019 Jan; 17(1):72-76. PubMed ID: 30450803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
    Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
    Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.